Vance Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Vance Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$283K	Hold	1,786	–	–	0.06%	111
2026 Q1	$228K	Hold	1,786	–	–	0.07%	109
2025 Q4	$218K	Buy	+1,786	New	+$205K	0.06%	113

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Vance Wealth's XBI Position: Q2 2026 in Review

Vance Wealth held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 1,786 shares worth $283K. The position accounts for 0.06% of the portfolio, ranked #111.

Vance Wealth first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Vance Wealth held 1,786 shares of State Street SPDR S&P Biotech ETF worth $283K as of Q2 2026.
Vance Wealth left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.06% of Vance Wealth's portfolio in Q2 2026, its #111 holding.
Vance Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Vance Wealth's 13F filing for Q2 2026, filed 14 Aug 2026.